NCT06033768 is a clinical trial in Neurocutaneous Syndromes, sponsored by Assiut University.

Who is sponsoring NCT06033768?

NCT06033768 is sponsored by Assiut University.

What condition does NCT06033768 study?

NCT06033768 studies Neurocutaneous Syndromes.

Is NCT06033768 still recruiting?

NCT06033768 is currently status unknown. Last updated 13 September 2023.

Last reviewed 2023-09-13 · How we verify

NCT06033768

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neurological and Psychological Assessment of Neurocutaneous Syndromes in Upper Egypt Children

Status unknown Last updated 13 September 2023

What this trial tests

trial in Neurocutaneous Syndromes in 200 participants. Status unknown.

Timeline

1 October 2023

Primary endpoint
1 October 2025

1 December 2025

Quick facts

Lead sponsor	Assiut University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	200
Start date	1 October 2023
Primary completion	1 October 2025
Estimated completion	1 December 2025

Conditions studied

Neurocutaneous Syndromes — all drugs for Neurocutaneous Syndromes →

Sponsor

Assiut University

Who can join

Adults 1 Month to 18, any sex, with Neurocutaneous Syndromes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluation of neurological and psychological complications in children diagnosed as neurocutaneous syndromes in upper Egypt

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06033768 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 13 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06033768.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing